Related references
Note: Only part of the references are listed.Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2021)
Better Medicines for Older Patients: Considerations between Patient Characteristics and Solid Oral Dosage Form Designs to Improve Swallowing Experience
Nelio Drumond et al.
PHARMACEUTICS (2021)
Proton Pump Inhibitors and Oncologic Treatment Efficacy: A Practical Review of the Literature for Oncologists
Angel A. T. Uchiyama et al.
CURRENT ONCOLOGY (2021)
Harnessing the therapeutic potential of anticancer drugs through amorphous solid dispersions
Urvi H. Gala et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2020)
A Systematic Review of Gastric Acid-Reducing Agent-Mediated Drug-Drug Interactions with Orally Administered Medications
Divya Patel et al.
CLINICAL PHARMACOKINETICS (2020)
In vivo measurement of gastric fluid volume in anesthetized dogs
Cuncai Wang et al.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY (2020)
Clinical implications of food–drug interactions with small-molecule kinase inhibitors
G D Marijn Veerman et al.
LANCET ONCOLOGY (2020)
Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary
Masoud Jamei et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2020)
Novel High-Drug-Loaded Amorphous Dispersion Tablets of Posaconazole; In Vivo and In Vitro Assessment
Deanna M. Mudie et al.
MOLECULAR PHARMACEUTICS (2020)
Characterization of the GI transit conditions in Beagle dogs with a telemetric motility capsule
Mirko Koziolek et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2019)
Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part I. Mechanistic modelling of drug product dissolution to derive a P-PSD for PBPK model input
Xavier J. H. Pepin et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2019)
Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices
Xavier J. H. Pepin et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2019)
Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans
Terry Podoll et al.
DRUG METABOLISM AND DISPOSITION (2019)
Biopharmaceutic IVIVE-Mechanistic Modeling of Single- and Two-Phase In Vitro Experiments to Obtain Drug-Specific Parameters for Incorporation Into PBPK Models
Shriram M. Pathak et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2019)
Measuring the Impact of Gastrointestinal Variables on the Systemic Outcome of Two Suspensions of Posaconazole by a PBPK Model
Bart Hens et al.
AAPS JOURNAL (2018)
Considerations for the development of in vitro dissolution tests to reduce or replace preclinical oral absorption studies
Elise Grignard et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
Low Buffer Capacity and Alternating Motility along the Human Gastrointestinal Tract: Implications for in Vivo Dissolution and Absorption of Ionizable Drugs
Bart Hens et al.
MOLECULAR PHARMACEUTICS (2017)
In Vitro Characterization of Ritonavir Drug Products and Correlation to Human in Vivo Performance
Hao Xu et al.
MOLECULAR PHARMACEUTICS (2017)
Inventory of oral anticancer agents: Pharmaceutical formulation aspects with focus on the solid dispersion technique
E. Sawicki et al.
CANCER TREATMENT REVIEWS (2016)
Characterization of Human Duodenal Fluids in Fasted and Fed State Conditions
Danny Riethorst et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2016)
Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs
Shrawan Baghel et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2016)
Characteristics of the Human Upper Gastrointestinal Contents in the Fasted State Under Hypo- and A-chlorhydric Gastric Conditions Under Conditions of Typical Drug - Drug Interaction Studies
Chara Litou et al.
PHARMACEUTICAL RESEARCH (2016)
Variability in bioavailability of small molecular tyrosine kinase inhibitors
Maikel Herbrink et al.
CANCER TREATMENT REVIEWS (2015)
Assessment of the Amorphous Solubility of a Group of Diverse Drugs Using New Experimental and Theoretical Approaches
Luis Almeida e Sousa et al.
MOLECULAR PHARMACEUTICS (2015)
pH-Dependent Drug-Drug Interactions for Weak Base Drugs: Potential Implications for New Drug Development
L. Zhang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Use of the pentagastrin dog model to explore the food effects on formulations in early drug development
P. Zane et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2014)
Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective
Roelof W. F. van Leeuwen et al.
LANCET ONCOLOGY (2014)
Dissolution media simulating the proximal canine gastrointestinal tract in the fasted state
Marcel Arndt et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2013)
Prevalence of Acid-Reducing Agents (ARA) in Cancer Populations and ARA Drug-Drug Interaction Potential for Molecular Targeted Agents in Clinical Development
Gillian S. Smelick et al.
MOLECULAR PHARMACEUTICS (2013)
Impaired Drug Absorption Due to High Stomach pH: A Review of Strategies for Mitigation of Such Effect To Enable Pharmaceutical Product Development
Amitava Mitra et al.
MOLECULAR PHARMACEUTICS (2013)
Swallowing dysfunction in cancer patients
Judith E. Raber-Durlacher et al.
SUPPORTIVE CARE IN CANCER (2012)
Development of a Canine Model to Enable the Preclinical Assessment of Ph-dependent Absorption of Test Compounds
R. Marcus Fancher et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2011)
Using Absorption Simulation and Gastric pH Modulated Dog Model for Formulation Development To Overcome Achlorhydria Effect
Amitava Mitra et al.
MOLECULAR PHARMACEUTICS (2011)
Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers
R Tutuian et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2002)
Share Paper
